Companies · Biotechnology

Micell Technologies Inc

Durham · Biotechnology

Diligence memoA one-page analyst read on Micell Technologies Inc — recommendation, valuation, rhythm, risks.
$62.1M
Total raised · real
2
Rounds
1.5×
Latest step-up
Top 16%
Sector rank · raised
Series C
Latest stage · inferred · Fri Sep 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Micell Technologies Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.24× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
  • Within the normal band (124% of peer median) for its niche.
Dormant
  • Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Micell Technologies Inc is one of 4291 Biotechnology companies tracked from Durham. By capital raised it ranks in the upper tier (ahead of 85% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
51
Investors (latest)
2017-09-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2009-07-17 Raised $5.0M (real) Modeled valuation $181M (est)$5.0M$181MSeries A2009Series A · 2009-11-19 Raised $300K (real) Modeled valuation $11M (est)$300K$11MSeries A2009Series B · 2016-06-20 Raised $26M (real) Modeled valuation $1.0B (est)$26M$1.0BSeries B2016Series B · 2017-03-28 Raised $32M (real) Modeled valuation $1.3B (est)$32M$1.3BSeries B2017Series C · 2017-06-16 Raised $42M (real) Modeled valuation $1.7B (est)$42M$1.7BSeries C2017Series C · 2017-09-01 Raised $62M (real) Modeled valuation $2.5B (est)$62M$2.5BSeries C2017+$300K+$26M+$32M+$42M+$62MCumulative $166M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.0M · 2009
Series A extension$300K · 2009
Series B$25.8M · 2016
Series B extension$31.8M · 2017
Series C$41.8M · 2017
Series C extension$61.8M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$2.5B
Base estimate est.
$191.1M
Conservative case
$6.7B
Upside case
$411.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $180.8M · 2009-07-172009Series A · modeled $10.8M · 2009-11-19Series B · modeled $1.0B · 2016-06-20Series B · modeled $1.3B · 2017-03-28Series C · modeled $1.7B · 2017-06-16Series C · modeled $2.5B · 2017-09-012017
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
6.0 yr
Elapsed time used
8.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
20 mo
Avg between rounds
$7.6M/yr
Capital velocity
17.0 yr
On record since
2009
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.6× above median
This company$62.1M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.3× above median
This company$61.8M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 39× above median
This company$2.5B
Sector median$64.2M

Raised more than 85% of sector peers (real $). Modeled value above 96% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #12 of 41.

This companyCohort peer
$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Genesis Biopharma, Inc · Series C Raised $131.5M · modeled $4.1B (est)Alder Biopharmaceuticals Inc · Series C Raised $100.0M · modeled $4.1B (est)Ideaya Biosciences, Inc. · Series C Raised $111.4M · modeled $3.9B (est)Stoke Therapeutics, Inc. · Series C Raised $90.8M · modeled $3.7B (est)4D Molecular Therapeutics Inc · Series C Raised $108.6M · modeled $3.7B (est)Sutro Biopharma Inc · Series C Raised $85.4M · modeled $3.5B (est)Evelo Biosciences, Inc. · Series C Raised $131.5M · modeled $3.3B (est)Celularity Inc. · Series C Raised $117.7M · modeled $3.2B (est)Codiak BioSciences, Inc. · Series C Raised $107.5M · modeled $3.1B (est)Arcturus Therapeutics Ltd. · Series C Raised $67.8M · modeled $2.8B (est)Celldex Therapeutics, Inc. · Series C Raised $64.5M · modeled $2.6B (est)Micell Technologies Inc (this company) Raised $62.1M · modeled $2.5B (est)Micell Technologies Inc
CompanyStageRaised · realValue · estvs peer med.
Genesis Biopharma, IncSeries C$131.5M$4.1B2.00×
Alder Biopharmaceuticals IncSeries C$100.0M$4.1B2.00×
Ideaya Biosciences, Inc.Series C$111.4M$3.9B1.88×
Stoke Therapeutics, Inc.Series C$90.8M$3.7B1.80×
4D Molecular Therapeutics IncSeries C$108.6M$3.7B1.80×
Sutro Biopharma IncSeries C$85.4M$3.5B1.71×
Evelo Biosciences, Inc.Series C$131.5M$3.3B1.63×
Celularity Inc.Series C$117.7M$3.2B1.55×
Codiak BioSciences, Inc.Series C$107.5M$3.1B1.53×
Arcturus Therapeutics Ltd.Series C$67.8M$2.8B1.36×
Celldex Therapeutics, Inc.Series C$64.5M$2.6B1.25×
Micell Technologies Inc this companySeries C$62.1M$2.5B1.24×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.0M2009-07-17$22.7M$180.8M85%
Series A$300K2009-11-19$1.4M$10.8M85%
Series B$25.8M2016-06-20$143.2M$1.0B90%
Series B$31.8M2017-03-28$176.5M$1.3B90%
Series C$41.8M2017-06-16$278.5M$1.7B90%
Series C$61.8M2017-09-01$411.8M$2.5B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.0M2009-07-17
    • First recorded raise — entered as Series A.
    • 9 investors on this round.
  2. Series A$300K2009-11-19
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 16.7× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  3. Series B$25.8M2016-06-20
    • Raised again after 79 mo — slower than the ~14 mo sector norm.
    • Round 85.9× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 51 investors on this round.
  4. Series B$31.8M2017-03-28
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 51 investors on this round.
  5. Series C$41.8M2017-06-16
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 51 investors on this round.
  6. Series C$61.8M2017-09-01
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 51 investors on this round.
Intelligence
2019 ~Q2
Modeled next raise · ~20mo cadence
$91.4M
Modeled next size est.range $61.8M$146.2M
1.5×
Last step-up
$7.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Langer35 other2009-07
Robert S Langer13 other2016-06
Archibald Cox, Jr.5 other2009-07
Kenneth Langone3 other2009-07
Robert A. Langer2 other2009-11
Archibald A. Cox2016-06
Archibald B Cox, Jr.2009-11
Archibald J. Cox2017-03
Arthur J. Benevenuto2009-07
Arthur J Benvenuto2009-11
Daniel G. Estay2016-06
David A. Dresner2009-07
Jack A. Herman2009-11
James A. Klein2016-06
James A. Klein, Jr.2009-11
James B McClain2009-11
John G. Lowry2016-06
Kenneth G Langone2009-11
Michael G. Stansky2016-06
Stewart Noble, Ph.D.2009-07
Timothy G. McMahon2017-06
Registry & provenance

Micell Technologies Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1060368
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
MicroCHIPS, Inc.BiotechnologySeries B$27.9M$740.1Mnetwork2 shared operators · same sector
Predictive Biosciences, IncBiotechnologySeries B$26.8M$1.0Bnetwork2 shared operators · same sector
Fibrocell Science, Inc.BiotechnologySeries C$108.6M$36.9Mnetwork1 shared operator · same sector · same stage
Glympse Bio, Inc.BiotechnologySeries C$114.0M$324.7Mnetwork1 shared operator · same sector · same stage
Lyndra, Inc.BiotechnologySeries D+$281.9M$1.6Bnetwork2 shared operators · same sector
Frequency Therapeutics, Inc.BiotechnologySeries C$136.3M$1.7Bnetwork1 shared operator · same sector · same stage
StemBioSys Inc.BiotechnologySeries A$9.9M$43.8Mnetwork2 shared operators · same sector
KALA BIO, Inc.BiotechnologySeries C$158.8M$8.3Mnetwork1 shared operator · same sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Starling Medical, Inc.BiotechnologySeries A$1.9M86%
Rll, LlcBiotechnologySeries A$173.0M85%
Mouse LLCBiotechnologyPre-Seed$5.5M85%
Martell Diagnostic Laboratories, Inc.BiotechnologyPre-Seed$5.9M84%
Thrivell Holdings, LlcBiotechnologyPre-Seed$24.4M84%
Saral, Inc.BiotechnologySeries D+$2.6B84%
Kellbenx Inc.BiotechnologySeries A$21.3M84%
Seedling Biosystems Inc.BiotechnologyPre-Seed$886K83%
Frequently asked
How much funding has Micell Technologies Inc raised?
Micell Technologies Inc has raised approximately $62.1M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Micell Technologies Inc's estimated valuation?
Provath's modeled valuation for Micell Technologies Inc is approximately $2.5B (modeled range $191.1M–$6.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Micell Technologies Inc at?
Micell Technologies Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Sep 01.
What does Micell Technologies Inc do and where is it based?
Micell Technologies Inc operates in the Biotechnology sector, based in Durham.
Explore related

See where Micell Technologies Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Micell Technologies Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.